| |
RA patients (n=18) |
Healthy controls (n=18) |
| Age mean ± SD in years |
60.4 ± 13.8 |
46.4 ± 18.2 |
| Female:Male ratio |
1:1.6 |
1:2 |
| Duration of RA, y, median (range) |
12 (2-34) |
|
| DASb median (range) |
4.4 (1.26-7.5) |
|
| Methotrexate, n (%) |
10/18 (55.5) |
|
| Prednisone, n (%) |
4/18 (22.2) |
|
| Plaquenil, n (%) |
6/18 (33.3) |
|
| RAa, rheumatoid arthritis; bDAS, disease activity score |
|
